Reduced expression of the p27 cell cycle inhibitor predicts poor cancer patient survival (pages 222–234).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein
Oncogene Open Access 21 June 2018
-
Roles of the Skp2/p27 axis in the progression of chronic nephropathy
Cellular and Molecular Life Sciences Open Access 20 December 2012
-
Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases
BMC Systems Biology Open Access 13 June 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Catzavelos, C. et al. Decreased levels of the cell cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Med. 3, 227–230 (1997).
Porter, P. et al. Expression of cell cycle regulators p27 Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222–226 (1997).
Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231–234 (1997).
Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1 Cell 85, 721–732 (1996).
Nakayama, K. et al. Mice lacking p27 Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 85, 707–720 (1996).
Hengst, L. & Reed, S. Translational control of p27 Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996).
Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).
Muss, H. et al. c-erb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl. J. Med. 330, 1260–1266 (1994).
Thor, A. et al. Selecting patients for higher dose adjuvant CAF: c-erb-B-2, p53 (CALGB 8869 and 8541). Proc. American Society of Clinical Oncology (in the press).
Emmert-Buck, M. et al. Laser capture microdissection. Science 274, 998–1001 (1996).
To affinity … and beyond! Nature Genet 14, 367–370 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steeg, P., Abrams, J. Cancer prognostics: Past, present and p27. Nat Med 3, 152–154 (1997). https://doi.org/10.1038/nm0297-152
Issue Date:
DOI: https://doi.org/10.1038/nm0297-152
This article is cited by
-
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein
Oncogene (2018)
-
Roles of the Skp2/p27 axis in the progression of chronic nephropathy
Cellular and Molecular Life Sciences (2013)
-
Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases
BMC Systems Biology (2012)
-
Evaluation of P53, P63, P21, P27, Ki-67 in Paranasal Sinus Squamous Cell Carcinoma and Inverted Papilloma
Indian Journal of Otolaryngology and Head & Neck Surgery (2011)
-
Adenovirus Expressing Mutant p27 kip1 Enhanced Apoptosis and Inhibited the Growth of Xenografted Human Breast Cancer
Surgery Today (2007)